Davis Polk advised the representatives of the several underwriters in connection with the $1.3 billion initial public offering of 39,807,691 shares of Class A common stock of GoodRx Holdings, Inc., of which 28,615,034 shares were issued and sold by GoodRx and 11,192,657 shares were sold by the selling shareholders. The shares include 5,192,307 sold by GoodRx from the full exercise of the underwriters’ option to purchase additional shares. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol “GDRX.”
GoodRx was founded to solve the challenges that consumers face in understanding, accessing and affording healthcare. GoodRx started with a price comparison tool for prescriptions, and today, its expanded platform provides access to price transparency and affordability solutions for generic and brand medications, affordable and convenient medical provider consultations via telehealth and additional healthcare services and information. GoodRx is headquartered in Santa Monica, California.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Donald K. Lang and Sylvia Zaich. The intellectual property and technology transactions team included partner Frank J. Azzopardi and associates S. Dream Montgomery and Daniel P. Kearney. The tax team included counsel Ethan R. Goldman and associate Eitan Ulmer. Counsel Marcie A. Goldstein provided FINRA advice. Associate Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.